



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH



European Network of Centres for
Pharmacoepidemiology and
Pharmacovigilance

EMA/95098/2010 Rev.9

The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology

Revision 9

ENCePP Guide, Revision 9 - Authorship

Editor

Catherine Cohet for the ENCePP Working Group *Research Standards and Guidance*

Design and layout

Julianna Fogd

Main authors

Foreword: Gianmario Candore, Susana Perez-Gutthann for the *ENCePP Steering Group*

1. Introduction: Xavier Kurz

2. Formulating the research question: Yola Moride, Massoud Toussi, Catherine Cohet

3. Development of the study protocol: Annie Fourier-Réglat, Catherine Cohet

4. Approaches to data collection

4.1.1 Primary data collection – general considerations: Susana Perez-Gutthann

4.1.2. Surveys: Massoud Toussi, Xavier Fournie, Nawab Qizilbash

4.1.3. Randomised clinical trials: Susana Perez-Gutthann

4.2. Secondary use of data: Susana Perez-Gutthann, Gianluca Trifirò

4.3. Patient registries: Xavier Kurz

4.4. Spontaneous reports: Gianmario Candore, Eugene van Puijenbroek, Niklas Norèn, Jim Slattery

4.5. Social media: Massoud Toussi, Annie Fourier-Reglat, Priya Bahri, Niklas Norèn

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



4.6. Research networks for multi-database studies: Gianmario Candore, Alexandra Pacurariu, Deborah Layton

5. Study design

5.1. Overview: Alejandro Arana

5.2. Types of study designs: Xavier Kurz, Jesper Hallas

5.3. Definition and validation of drug exposure, outcomes and covariates: Gillian Hall, Jesper Hallas

5.4. Specific aspects of study design

5.4.1. Pragmatic trials and large simple trials: Tjeerd van Staa, Olaf Klungel

5.4.2. The target trial approach: Tania Schink, Vera Ehrenstein, Gillian Hall, Olaf Klungel, Jesper Hallas, Xavier Kurz

5.4.3. Self-controlled case series and self-controlled risk interval designs: Catherine Cohet

5.4.4. Positive and negative control exposures and outcomes: Gillian Hall, Vera Ehrenstein, Tania Schink, Olaf Klungel, Jesper Hallas

5.4.5. Use of an active comparator: Vera Ehrenstein, Gillian Hall, Tania Schink, Olaf Klungel, Jesper Hallas

5.4.6. Interrupted time series analysis: Vera Ehrenstein, Gillian Hall, Tania Schink, Jesper Hallas, Olaf Klungel

5.4.7. Case-population studies: Ursula Kirchmayer

6. Methods to address bias and confounding

6.1. Bias: Alexandra Pacurariu, Vera Ehrenstein, Olaf Klungel, Jesper Hallas, Ursula Kirchmayer, Alejandro Arana

6.2. Confounding: Alexandra Pacurariu, Vera Ehrenstein, Olaf Klungel, Jesper Hallas, Ursula Kirchmayer, Alejandro Arana

6.3. Missing data: Chantal Quinten, Jim Slattery

6.4. Triangulation: Vera Ehrenstein, Gillian Hall, Tania Schink, Jesper Hallas, Olaf Klungel

7. Effect measure modification and interaction: Olaf Klungel, Federica Pisa

8. Systematic reviews and meta-analysis: Daniel Morales

9. Signal detection methodology and application: Gianmario Candore, Niklas Norèn, Jim Slattery, Eugene van Puijenbroek

10. The statistical analysis plan: Chantal Quinten, Jim Slattery

11. Quality management: Milena Jadrijević-Mladar Takač

12. Dissemination and communication of study results: Susana Perez-Gutthann, Gillian Hall, Tania Schink

13. Data protection and ethical aspects

13.1. Patient and data protection: Sabine Brosch, Orsolya Eotvos

13.2. Scientific integrity and ethical conduct: Xavier Kurz

14. Specific topics

14.1. Comparative effectiveness research: Annie Fourrier-Réglat, Olaf Klungel, Federica Pisa

14.2. Vaccine safety and effectiveness: Catherine Cohet, Xavier Kurz

14.3. Design, implementation and analysis of pharmacogenetic studies: Maria Gordillo-Marañón, Sonali Sanghvi, Aroon Hingorani, Reecha Sofat

14.4. Methods for pharmacovigilance impact research: Thomas Goedecke, Helga Gardarsdottir, Alexandra Pacurariu, Daniel Morales for the *ENCePP Special Interest Group on Measuring the Impact of Pharmacovigilance Activities*

Annex 1: Nawab Qizilbash, Daniel Morales

Acknowledgements

From the 1st to the 9th revisions, peer review of one or several chapters was received from:

Alfonso Carvajal	Martin Daumer
Amalia Issa	Michael Theodorakis
Ana Marta Anes	Mirko Di Martino
Ann Daly	Munir Pirmohamed
Annalisa Rubino	Nada Božina
Brian Strom	Nancy Dreyer
Camilla Stephens	Paddy Farrington
Consuelo Pedros	Patrick Zuber
David Martin	Peter Arlett
Elisabetta Poluzzi	Phillip Bryan
Frank DeStefano	Robert Vander Stichele
Geoff Liu	Rolf Groenwold
Gillian Bartlet	Samy Suissa
Gonzalo Calvo	Sarah McFarlane
Gunilla Sjolín-Forsberg	Sebastian Botzenhardt
Hervé Le Louet	Sebastian Schneeweiss
Hubert Leufkens	Stefanie Prilla
Ivana Silva	Stephen Evans
Jan Bonhoeffer	Teresa Herdeiro
John Parkinson	Ulf Bergman
Kevin Blake	Victoria Newbould
Kenneth J. Rothman	Viktor Kiri
Lina Titievski	Wei Zhou
Marina Davoli	Yvonne Lis
Mark de Groot	